PDSB

PDS Biotechnology Corporation

2.98 USD
+0.34 (+12.67%)
Last updated
This page is just a preview of the data found in TrendSpider’s full version

PDS Biotechnology Corporation stock is down -37% since 30 days ago. The next earnings date is May 13, 2024. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a red month, as 33.33% of the previous 8 April’s closed higher than March. In the last 2 Unusual Options Trades, there were 1 PUT, 1 CALL. 100% of analysts rate it a buy.

Options Flow Last 10
Date & Time Expiration Date Strike Price Trade Type Size Open Interest
27 Mar 14:28 19 Apr, 2024 5.00 PUT 308 2071
28 Mar 17:54 16 Aug, 2024 5.00 CALL 300 701

About PDS Biotechnology Corporation

PDS Biotechnology Corporation focuses on developing multifunctional cancer immunotherapies. Its lead product candidate is PDS0101 (HPV16), which is in Phase II clinical trial provides a first line treatment for the recurrent/metastatic head and neck cancer, human papillomavirus associated malignancies, and cervical cancer. The company is also developing various product candidates, which are in preclinical trials.

  • B. Riley
    Thu Mar 28, 11:59
    buy
    confirm
  • HC Wainwright & Co.
    Wed Mar 27, 10:27
    buy
    confirm